NEW YORK, Jan. 13, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Enfusion, Inc. (NYSE: ENFN) and its board of directors concerning the proposed acquisition of the company by Clearwater Analytics (NYSE: CWAN). Stockholders will receive a mix of shares of Clearwater Analytics common stock and cash worth $11.25 for each share of Enfusion stock that they hold. The transaction is valued at approximately $1.5 billion and is expected to close in the second quarter of ...

NEW YORK, Jan. 13, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Enfusion, Inc. (NYSE: ENFN), relating to the proposed merger with Clearwater Analytics. Under the terms of the agreement, Enfusion shareholders will receive $5.85 per share in cash and $5.40 ...

Exhibit 2.1 EXECUTION COPY AGREEMENT AND PLAN OF MERGER by and among ENFUSION, INC., ENFUSION LTD. LLC, CLEARWATER ANALYTICS HOLDINGS, INC. POSEIDON ACQUIRER, INC. POSEIDON MERGER SUB I, INC. and POSEIDON MERGER SUB II, LLC JANUARY 10, 2025 TABLE OF CONTENTS | | Page | | --- | --- | | ARTICLE I DEFINITIONS | 2 | | Section 1.01 Definitions | 2 | | Section 1.02 Other Defined Terms | 20 | | Section 1.03 Other Definitional and Interpretative Provisions | 24 | | ARTICLE II THE MERGERS | 25 | | Section 2.01 The C ...

I wrote about Enfusion (NYSE: ENFN ) previously ( in August ) with a buy rating as management showed promising execution in its effort to move upmarket, and that growth should recover when theI am an individual investor that is now fully focus on managing my own capital that I have saved up over the years. My investing background spreads across a wide spectrum as I believe there are merits to each approach, for instance: Fundamental investing [Bottoms-up etc.], Technical investing [historical charts analysi ...

Enfusion, Inc. (ENFN) shares rallied 5% in the last trading session to close at $8.98. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.3% gain over the past four weeks. Enfusion is benefiting from robust client acquisition and successful expansion into institutional asset management markets. This company is expected to post quarterly earnings of $0.06 per share in its upcoming report, which represents a yea ...

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE: ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN. Investigation Details On August 6, 2024, Enfusion reported its financial results for the second quarter of 2024. The Compa ...

Alistair Berg Investment overview I wrote about Enfusion (NYSE:ENFN) previously (late March this year) with a buy rating, as the growth outlook remained positive and was well-supported by good execution. I remain buy-rated for ENFN as I liked the execution that management is demonstrating so far, specifically in winning new customers in launch markets and penetrating the upmarket. The current hurdle to growth acceleration seems to be a macro problem that should recover in due time. 2Q24 earnings (announced ...

Financial Data and Key Metrics Changes - Enfusion reported Q2 2024 revenue of $49.5 million, representing a 16% year-over-year growth [7][30] - Adjusted EBITDA for Q2 2024 totaled $10.1 million, with an adjusted EBITDA margin of 20.5%, up 190 basis points from the previous year [34] - Annual recurring revenue (ARR) reached $195.7 million, up 14% year-over-year [32] - Adjusted free cash flow for the quarter was $4.6 million, with a free cash flow conversion of 46% [34] Business Line Data and Key Metrics Changes - Enfusion signed 39 new clients in Q2 2024, increasing total client count to 879 [7] - Average contract value (ACV) increased from $226,000 to $228,000, marking a 7.5% year-over-year growth [8] - The company continues to focus on moving up-market, targeting larger asset managers while maintaining its core hedge fund segment [8][10] Market Data and Key Metrics Changes - Revenue in the Americas grew 15% year-over-year, with notable strength in U.S. fund launches [9] - Asia Pacific revenue grew 10% year-over-year, despite geopolitical and macroeconomic headwinds [12] - EMEA revenue grew 28% year-over-year, reflecting strong momentum and diversification beyond the U.K. [15][16] Company Strategy and Development Direction - Enfusion aims for a revenue growth rate of over 20% from 2025 to 2027, focusing on institutional asset managers and enhancing service delivery [5][6] - The company is investing in its services platform to empower clients and improve operational efficiencies [6][19] - Enfusion is expanding its partnerships with consultants and system integrators to enhance its market presence in the institutional asset management space [45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's resilience to macroeconomic forces, highlighting a strong demand for modern investment technology [26][58] - The company anticipates continued growth in client onboarding and conversions, despite some short-term volatility in the back book [36][55] - Management remains optimistic about the long-term growth potential, even amid potential interest rate changes [58] Other Important Information - Enfusion's mobile app and Portfolio Workbench tool enhancements are expected to drive client satisfaction and operational efficiencies [20][21] - The company has made key hires to strengthen its product management and transformation teams [24] Q&A Session All Questions and Answers Question: Impact of product enhancements on win rates and bookings - Management indicated that enhancements like the Portfolio Workbench are essential for institutional asset managers and have improved client acquisition and pipeline opportunities [40][41] Question: Churn trends and their impact on the back book - Management noted that churn has normalized, but upsell opportunities remain a focus for improvement in the back book [42][43] Question: Role of partnerships in the services ecosystem - Management confirmed that partnerships with consultants and system integrators are crucial for onboarding and implementation in the institutional asset management sector [44][45] Question: Cross-sell opportunities in the back book - Management highlighted efforts in partnerships and product capabilities to enhance cross-sell opportunities, which are expected to yield dividends [49][50] Question: Guidance and macroeconomic visibility - Management maintained guidance amid macroeconomic uncertainty, emphasizing the strong performance of the front book and the need to monitor back book dynamics closely [55][56]

NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE: ENFN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Enfusion and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On or around October 21, 20 ...

Enfusion, Inc. (ENFN) reported $49.46 million in revenue for the quarter ended June 2024, representing a yearover-year increase of 15.8%. EPS of $0.05 for the same period compares to $0.04 a year ago. The reported revenue represents a surprise of -1.61% over the Zacks Consensus Estimate of $50.27 million. With the consensus EPS estimate being $0.06, the EPS surprise was -16.67%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...